Event Type
Disclosure
Voluntary
Variant
8-K
, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabil
. Other Events. On January 6, 2026, the Company issued a press release disclosing that it (i) filed a new drug application for lorundrostat to the U.S. Food and
. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release Issued on January 6, 2026 104 Cover Page Interactive Data File (emb